Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM)
Authors
Alexander Maxwell Menzies (ORCID: https://orcid.org/0000-0001-5183-7562)
Angela Hong (ORCID: https://orcid.org/0000-0003-3668-243X)
Serigne Lo (ORCID: https://orcid.org/0000-0001-5092-5544)
Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM)
Alexander Maxwell Menzies, Angela Hong, Serigne Lo, Georgina Venetia Long et al.
Journal
BMC Cancer
Topics
Cancer Immunotherapy and Biomarkers
article
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM)
Alexander Maxwell Menzies, Angela Hong, Serigne Lo, Georgina Venetia Long, Inês Pires da Silva, Matteo Salvatore Carlino, Wei Wang
article en
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 25(1)
Institutions
The University of Sydney (AU), Mater Health Services (AU), Royal North Shore Hospital (AU), Westmead Hospital (AU), Melanoma Institute Australia (AU)